



FINANCIAL TEAR SHEET

Corporate Profile

Abeona Therapeutics is focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. Developing therapies for rare disease requires new approaches and strong collaboration between researchers, industry, regulators and patient groups. Abeona was forged from the company's close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases such as Sanfilippo disorder, Batten disease, Fanconi anemia and other rare disorders.

Primary IR Contact

Andre'a Lucca
 Director of Communications
 PlasmaTech
 Biopharmaceuticals, Inc.
Phone: 212-786-6208
E-mail:
 alucca@plasmatechbio.com

Stock Performance

ABEO (Common Stock)

Exchange	NASDAQ CM (US Dollar)
Price	\$5.55
Change (%)	▼ 0.15 (2.63%)
Volume	142,573
52 Week Low	\$2.31
Market Cap	\$223,415,705
Rolling EPS	-0.60
PE Ratio	0
Shares Outstanding	40,255,082



Data as of May 26, 2017 4:00 p.m. ET

Recent Press Releases & Upcoming Events

May 25, 2017

Abeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa

May 19, 2017

Abeona Therapeutics to Present at Multiple Upcoming Conferences

May 16, 2017

Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights

Date	Title
May 31, 2017 through June 1, 2017	Neurotech Investing and Partnering Conference Location San Francisco, CA
June 6, 2017 through June 9, 2017	Jefferies 2017 Global International Healthcare Conference Location New York City, NY
June 13, 2017 through June 14, 2017	Plasma Protein Forum Location Washington, D.C

SEC Filings

Filing Date	Form
May 18, 2017	8-K
May 15, 2017	10-Q
May 3, 2017	EFFECT
April 25, 2017	POS AM

Corporate Governance

Data provided by Nasdaq. Minimum 15 minutes delayed.